RS53257B2 - Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa - Google Patents

Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa

Info

Publication number
RS53257B2
RS53257B2 RS20140158A RSP20140158A RS53257B2 RS 53257 B2 RS53257 B2 RS 53257B2 RS 20140158 A RS20140158 A RS 20140158A RS P20140158 A RSP20140158 A RS P20140158A RS 53257 B2 RS53257 B2 RS 53257B2
Authority
RS
Serbia
Prior art keywords
lentiviral vector
virus
polypeptide
antigen
seq
Prior art date
Application number
RS20140158A
Other languages
English (en)
Inventor
James M Allen
Hoeven Neal S Van
jin zhong Li
Derek D Sloan
Thomas W Dubensky Jr
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS53257(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of RS53257B publication Critical patent/RS53257B/sr
Publication of RS53257B2 publication Critical patent/RS53257B2/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (23)

  1. Patentni zahtevi 1. Čestice lentiviralnog vektora, naznačene time, što obuhvataju: (a) omotač koji se sastoji od (i) E2 glikobelančevine iz Sindbis-virusa sa SEQ ID BR: 1 gde 160X je odsutna ili je neka amino-kiselina koja je različita od glutaminske kiseline, ili od varijante SEQ ID BR: 1 koja ima najmanje 80% identičnosti sa SEQ ID BR: 1 i gde 160X je odsutna ili je neka amino-kiselina koja je različita od glutaminske kiseline, koja je sposobna da inficira dendrite; pri čemu E2 nije deo fuzione belančevine sa E3 iz Sindbis-virusa; i (b) genom lentiviralnog vektora koji obuhvata jednu ili više sekvenci od interesa.
  2. 2. Čestica lentiviralnog vektora iz zahteva 1, naznačena time, što je u njoj 160X odsutna ili je glicin, alanin, valin, leucin ili izoleucin, na primer je izabrana iz glicina, valina, leucina ili izoleucina.
  3. 3. Čestica lentiviralnog vektora iz zahteva 1 ili 2, naznačena time, što varijanta E2 glikobelančevine ima najmanje jednu amino-kiselinu koja je promenjena sa ciljem da se smanji njen neto pozitivni naboj.
  4. 4. Čestica lentiviralnog vektora iz zahteva 3, naznačena time, što najmanje jedna aminokiselina koja treba da se promeni sa ciljem da se smanji neto pozitivni naboj je izabrana iz lizina 70, lizina 76 ili lizina 159 iz SEQ ID BR: 1, pri čemu su supstitucije preferirano nezavisno izabrane iz glutaminske kiseline ili asparaginske kiseline.
  5. 5. Čestica lentiviralnog vektora iz zahteva 1, naznačena time, što sekvenca E2 varijante sadrži amino-kiselinske ostatke 66 do 488 iz SEQ ID BR: 3, amino-kiselinske ostatke 66 do 488 iz SEQ ID BR: 4, ili amino-kiselinske ostatke 66 do 486 iz SEQ ID BR: 5; (varijante 1, 2 i 3).
  6. 6. Čestica lentiviralnog vektora iz zahteva 1-5, naznačena time, što predstavlja varijantu u kojoj sekvenca sa ostacima 71-75 iz SEQ ID BR: 1 nije promenjena ili ima jednu ili dve supstitucije koje ne utiču na sposobnost pomenute varijante da inficira DC, ali ne menjaju broj amino-kiselina u tom regionu.
  7. 7. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1-6, naznačena time, što sekvenca od interesa eksprimira produkt koji je antigen iz agensa koji uzrokuje bolest ili iz bolesne ćelije.
  8. 8. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1-6, naznačena time, što sekvenca od interesa kodira tumor-specifični antigen, ponekad NY-ESO-1, MAGE, MART-l/Melan-A, BAGE, RAGE, antigen iz linije melanocitnog melanoma, poput gp 100, gp75, mda-7, tirozinaze ili belančevine slične tirozinaze; antigen iz karcinoma bubrežnih ćelija, 5T4, SM22-alfa, karbonsku anhidrazu I, kartonsku anhidrazu IX (takođe poznatu kao G250), faktore koji se induciraju hipoksijom (ponekad, HIF-1 alfa ili HIF-2alfa), VEGF ili membranski antigen specifičan za prostatu (PSMA), antigen specifičan za prostatu (PSA), fosfati prostatne kiseline, šest-transmembranski epoitelijalni antigen iz prostate (STEAP), NKX3.1, epitop belančevina/peptida koji su dobiveni iz gena koji mutiraju u tumorskim ćelijama ili gena koji se transkribiraju u drugačijim nivoima u tumoru u odnosu na normalne ćelije, poput encima telomeraze, survivina, mezotelina, mutiranog ras, bcr/abl rearanžmana, Her2/neu, mutiranog ili divljeg-tipa p53, citohroma P450 1B1 , nenormalno eksprimiranih intronskih sekvenca poput N-acetilglukozaminiltransferaze-V; klonalni rearanžmani imunoglobulinskih gena koji generišu jedinstvene idiotipove mijeloma ili limfoma B-ćelija; epitop belančevina/peptida koji su dobiveni tokom onkoviralnih procesa, poput belančevine E6 ili E7 iz humanog papiloma-virusa; ili ne-mutirane onkofetalne belančevine sa tumorselektivnom ekspresijom, poput karcinoembrionskog antigena ili alfa-fetobelančevine.
  9. 9. Čestica lentiviralnog vektora iz bilo kojeg od zahteva od 1 - 7 , naznačena time, što sekvenca od interesa kodira antigen izveden iz virusa, poput antigena iz HIV ili SIV, polipeptida adenovirusa, polipeptida alfavirusa, polipeptida kalicivirusa, tj., antigen iz kapsida kalicivirusa, polipeptida koronavirusa, polipeptida distemper-virusa, polipeptida Ebola- virusa, polipeptida enterovirusa, polipeptida flavivirusa, polipeptida hepatitis virusa (AE), tj., antigen iz srži ili površine hepatitisa B, ili belančevine El ili E2 iz virusa hepatitisa C, srž, ili ne-strukturne belančevine, polipeptida herpesvirusa, tj., glikobelančevine iz herpessimpleks virusa ili virusa varicella-zoster, polipeptida virusa imunodificijencije, tj., omotač ili proteaza iz virusa humane imunodificijencije, polipeptida virusa infektivnog peritonitisa, polipeptida virusa influence, tj., hemaglutinin, neuraminidazu iz influence A; ili nukleobelančevina, polipeptida iz virusa leukemije, polipeptida Marburg-virusa, polipeptida ortomiksovirusa, polipeptida papiloma-virusa, polipeptida virusa parainfluence, tj., hemaglutinin/neuraminidaza, polipeptida paramiksovirusa, polipeptida parvovirusa, polipeptida pestivirusa, polipeptida pikoma-virusa, tj., polipeptida iz kapsida poliovirusa, polipeptida poks-virusa, tj., polipeptida vakcinija-virusa, polipeptida virusa besnila, tj., glikobelančevina G iz virusa besnila, polipeptida reovirusa, polipeptida retrovirusa, ili polipeptida rotavirusa.
  10. 10. Kompozicija koja obuhvata česticu lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, naznačena time, što sadrži IU od najmanje 10<5>/mL.
  11. 11. Sistem za pakovanje lentiviralnog vektora za proizvodnju pseudotipizirane čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što obuhvataju: (i) prvi molekul nukleinske kiseline koji kodira E2 glikobelančevinu iz Sindbis-virusa iz zahteva 1 (a)(i), i; (ii) drugi molekul nukleinske kiseline koji kodira gag- i pol-belančevinu, (iii) treći molekul nukleinske kiseline koji kodira rev; (iv) genom lentiviralnog vektora koji sadrži sekvencu od interesa; i (v) ćeliju za pakovanje.
  12. 12. Sistem za pakovanje lentiviralnog vektora iz zahteva l1, naznačen time, što: (a) pol-belančevina sadrži ne-funkcionalnu integrazu; i/ili (b) pol-belančevina sadrži ne-funkcionalnu integrazu sa D64V mutacijom; i/ili (c) genom lentiviralnog vektora je takav da ne može da se integriše; i/ili (d) ćelija za pakovanje je stabilno transformisana sa (ii) i (iii); i/ili (e) ćelija za pakovanje je transformisana sa (i) i (iv).
  13. 13. Izolovan molekul nukleinske kiseline, naznačen time, što obuhvata nukleotidnu sekvencu koja kodira E2 glikobelančevinu ili varijantu iz zahteva 1 (a)(i), ili bilo kojeg od zahteva od
  14. 14. Molekul nukleinske kiseline iz zahteva 13, naznačen time, što pomenuta belančevina je E3/E2/6K/El-polibelančevina iz Sindbis-a koja se obrađuje na način da E2 belančevina nije deo fuzione belančevine sa E3 kada se ugradi u viralni omotač.
  15. 15. Molekul nukleinske kiseline iz zahteva 14, naznačen time, što E3 sekvenca odgovara (a) ostacima 1-65 iz SEQ ID BR: 20, ili (b) njena varijanta ima najmanje 80% identičnosti sa ostacima 1-65 iz SEQ ID BR: 20, pri čemu ostaci 62-65 su RSKR (SEQ ID BR: 27), a pomenuta varijanta je sposobna da se ugradi u pseudotipizirani viralni omotač.
  16. 16. Postupak za proizvodnju čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10 koja sadrži kultiviranje lentiviralnog sistema iz zahteva 11.
  17. 17. Lentiviralna čestica iz bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što genom lentiviralnog vektora (a) sadrži inaktivisano ili samo-inaktivirajuće 3' dugo terminalno ponavljanje (LTR); i/ili (b) obuhvata U3-element kojemu nedostaje najmanje: (i) sekvenca-pojačivač; (j) (ii) TATA-kutija (iii) Sp 1-mesto (iv) NK-kapa B-mesto i (v) polipurinski trakt (PPT); i/ili (c) obuhvata nukleotidnu sekvencu iz SEQ ID BR: 21, 22 ili 23; i/ili, (d) obuhvata nukleotidnu sekvencu koja kodira faktor za sazrevanje/stimulisanje dendrita.
  18. 18. Čestica lentiviralnog vektora u skladu sa bilo kojem od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što se koriste u postupku za tretman ljudskog ili životinjskog subjekta, pri čemu tretman ponekad obuhvata dostavu čestica lentiviralnog vektora u dendrite ex vivo.
  19. 19. Čestice lentiviralnog vektora prema bilo kojeg od zahteva od 1-9, ili kompozicija iz zahteva 10, naznačeni time, što se koriste za indukovanje antigen-specifičnog imuno odgovora, ponekad humoralnog odgovora i/ili ćelijskog odgovora.
  20. 20. Terapeutsku ili profilaktičku vakcinu, naznačena time, što obuhvata čestice lentiviralnog vektora iz bilo kojeg od zahteva od 1-9, ili kompoziciju iz zahteva 10, i neki farmaceutski prihvatljivi ekscipijent.
  21. 21. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 20, naznačena time, što dodatno obuhvata neki dodatak.
  22. 22. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 21, naznačena time, što pomenuti dodatak je neki dodatak sa formulom (I):
    gde Al i A2 su nezavisno izabrani iz grupe koja obuhvata vodonik, fosfat, i fosfatne soli, a ostaci R<1>, R<2>, R<3>, R<4>, R<5>i R<6>su nezavisno izabrani iz grupe ugljovodonika koji imaju 3 do 23 ugljenika, a su predstavljeni sa<C3-C23.>
  23. 23. Terapeutska ili profilaktička vakcina u skladu sa zahtevom 22, naznačena time, što (a) Al je fosfat ili fosfatna so, a A2 je vodonik, i (b) (i) R<1>, R<3>, R<5>i R<6>su C<11>-C<20>alkil, a R<2>i R<4>su C<12>-C<20>ugljovodonik; ili (ii) R<1>, R<3>, R<5>i R<6>su C11alkil, a R<2>i R<4>su C<13>ugljovodonik; ili (iii) R<1>, R<3>, R<5>i R<6>su undecil, a R<2>i R<4>su tridecil. Izdaje i štampa: Zavod za intelektualnu svojinu, Beograd, Kneginje Ljubice 5
RS20140158A 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa RS53257B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
EP10737715.2A EP2456786B2 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Publications (2)

Publication Number Publication Date
RS53257B RS53257B (sr) 2014-08-29
RS53257B2 true RS53257B2 (sr) 2018-06-29

Family

ID=42727669

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20140158A RS53257B2 (sr) 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
RS20181505A RS58042B1 (sr) 2009-07-24 2010-07-22 Neintegrišući lentivirusni vektori

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20181505A RS58042B1 (sr) 2009-07-24 2010-07-22 Neintegrišući lentivirusni vektori

Country Status (27)

Country Link
US (3) US20110064763A1 (sr)
EP (2) EP2456786B2 (sr)
JP (4) JP2013500015A (sr)
KR (1) KR101790187B1 (sr)
CN (1) CN102482329B (sr)
AU (1) AU2010276194B2 (sr)
BR (1) BR112012001653A2 (sr)
CA (1) CA2768938C (sr)
CY (1) CY1121159T1 (sr)
DK (2) DK2456786T4 (sr)
EA (1) EA032403B1 (sr)
ES (2) ES2702274T3 (sr)
HR (2) HRP20140327T4 (sr)
HU (1) HUE043032T2 (sr)
IL (1) IL217679A (sr)
LT (1) LT2770061T (sr)
ME (1) ME01720B (sr)
MX (1) MX2012001075A (sr)
NZ (1) NZ597804A (sr)
PL (2) PL2456786T5 (sr)
PT (2) PT2456786E (sr)
RS (2) RS53257B2 (sr)
SG (1) SG177744A1 (sr)
SI (2) SI2456786T2 (sr)
SM (2) SMT201800656T1 (sr)
TR (1) TR201819229T4 (sr)
WO (1) WO2011011584A1 (sr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010274031B2 (en) * 2009-07-15 2015-07-16 Csl Behring Gene Therapy, Inc. Dual vector for inhibition of human immunodeficiency virus
US20120263754A1 (en) * 2011-02-15 2012-10-18 Immune Design Corp. Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines
AU2012243039B2 (en) * 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
EP3971286A3 (en) 2012-03-26 2022-04-20 The Regents of the University of California Nipah virus envelope pseudotyped lentiviruses and methods of use
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
DK2831095T3 (en) * 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
EP2943203A4 (en) * 2013-01-11 2016-08-24 Scripps Research Inst METHOD AND COMPOSITIONS FOR INCREASING THE TRANSDUCTION EFFICIENCY OF RETROVIRAL VECTORS
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
JP6822841B2 (ja) 2014-03-09 2021-01-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア オルニチントランスカルバミラーゼ（ｏｔｃ）欠損症の処置において有用な組成物
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
JP6760964B2 (ja) * 2015-01-21 2020-09-23 コーネル ユニバーシティ 異常ヘモグロビン症の予防及び治療のためのウイルスベクター
EP3250682A4 (en) * 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
WO2016149643A2 (en) 2015-03-18 2016-09-22 Omnicyte Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
DK3283658T3 (da) 2015-05-18 2020-05-18 Calimmune Inc Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
CA2997749A1 (en) 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
CA3004132A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
SG11201803546WA (en) * 2015-11-09 2018-05-30 Immune Design Corp Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
KR20180111874A (ko) 2016-02-23 2018-10-11 이뮨 디자인 코포레이션 멀티게놈 레트로바이러스 벡터 제제 및 이를 생산 및 사용하는 방법 및 시스템
CN109415416A (zh) * 2016-03-04 2019-03-01 纽约大学 用于诱导抗肿瘤免疫的表达肿瘤相关抗原的多表位的病毒介体
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Immunomodulatory proteins that are variants of CD80 and their uses
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Pd-l1 variant immunomodulatory proteins and uses thereof
ES3052812T3 (en) 2017-05-08 2026-01-14 Flagship Pioneering Innovations V Inc Compositions for facilitating membrane fusion and uses thereof
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
AU2019378036B2 (en) 2018-11-14 2026-05-07 Flagship Pioneering Innovations V, Inc Compositions and methods for compartment-specific cargo delivery
CN113348244B (zh) * 2018-11-23 2026-03-20 维拉治疗有限公司 Vsv嵌合载体
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
US20220364119A1 (en) 2019-06-14 2022-11-17 The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
US20220307050A1 (en) * 2019-08-01 2022-09-29 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
BR112023000730A2 (pt) * 2020-07-15 2023-10-03 Pasteur Institut Método para induzir e/ou ativar uma resposta imune, forma de dosagem, kit, vetor, célula hospedeira, partículas do vetor lentiviral pseudotipada e composição imunogênica
AU2022253020A1 (en) 2021-04-08 2023-10-26 Sana Biotechnology, Inc. Cd8-specific antibody constructs and compositions thereof
US11992524B2 (en) * 2021-10-25 2024-05-28 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery
CN119325517A (zh) * 2022-04-05 2025-01-17 生物辐射实验室股份有限公司 通过数字试验分析病毒颗粒
EP4522726A1 (en) 2022-05-09 2025-03-19 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
US12502437B2 (en) 2023-11-15 2025-12-23 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ES2060765T3 (es) 1988-05-17 1994-12-01 Lubrizol Genetics Inc Sistema promotor de ubiquitina en plantas.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (sr) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
WO1999061639A2 (en) * 1998-05-22 1999-12-02 Oxford Biomedica (Uk) Limited Retroviral delivery system
WO1998032869A1 (en) 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
JP2002538842A (ja) * 1999-03-16 2002-11-19 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 大量のスクリーニングのためのレンチウイルスベクター系
DK1175497T3 (da) * 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
EP1214437A1 (en) 1999-08-27 2002-06-19 The Regents of the University of California Use of lentiviral vectors for antigen presentation in dendritic cells
EP1221968B1 (en) 1999-10-13 2010-01-13 Novartis Vaccines and Diagnostics, Inc. Method of obtaining cellular immune responses from proteins
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
JP2004532012A (ja) * 2001-03-02 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド ウイルスリポーター粒子
CN100557023C (zh) * 2001-06-08 2009-11-04 株式会社载体研究所 利用vsv-g假型化猴免疫缺陷病毒载体将基因导入灵长类胚胎干细胞
AU2002326906C1 (en) 2001-09-13 2009-01-29 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
WO2003022228A2 (en) 2001-09-13 2003-03-20 California Institute Of Technology Method for producing transgenic birds and fish
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US6971999B2 (en) 2001-11-14 2005-12-06 Medical Instill Technologies, Inc. Intradermal delivery device and method
ES2374042T3 (es) 2002-02-04 2012-02-13 Becton, Dickinson And Company Dispositivo y método para suministrar o extraer una sustancia a través de la piel.
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
DK1499736T3 (da) * 2002-04-26 2009-06-08 Inst Nat Sante Rech Med Forbedrede kimære glycoproteiner og pseudotypet lentovirale vektorer
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
WO2004016280A1 (ja) 2002-08-16 2004-02-26 Japan Science And Technology Agency 組換えｂｃｇワクチン
AU2003297474A1 (en) 2002-12-18 2004-07-14 Salk Institute For Biological Studies Methods of inhibiting gene expression by rna interference
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
US20070275873A1 (en) * 2004-04-29 2007-11-29 Heidner Hans W Methods and Compositions Comprising Protein L Immunoglobulin Binding Domains for Cell-Specific Targeting
US20080227736A1 (en) * 2004-06-03 2008-09-18 Regents Of The University Of California, Targeting Pseudotyped Retroviral Vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US7429481B2 (en) * 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
CA2611056C (en) 2005-06-01 2016-06-28 California Institute Of Technology Method of targeted gene delivery using viral vectors
BRPI0714495B8 (pt) * 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
WO2009035528A2 (en) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Synthetic lipid a derivative
TR201802323T4 (tr) 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.

Also Published As

Publication number Publication date
US8187872B2 (en) 2012-05-29
ES2455544T5 (es) 2017-08-16
CN102482329B (zh) 2017-11-14
BR112012001653A2 (pt) 2016-11-08
SI2456786T1 (sl) 2014-05-30
MX2012001075A (es) 2012-05-22
US20120039932A1 (en) 2012-02-16
JP2017060535A (ja) 2017-03-30
RS53257B (sr) 2014-08-29
KR101790187B1 (ko) 2017-10-25
PT2770061T (pt) 2018-12-24
SI2770061T1 (sl) 2019-02-28
US20110064763A1 (en) 2011-03-17
IL217679A (en) 2016-09-29
JP2015109853A (ja) 2015-06-18
SMT201800656T1 (it) 2019-01-11
EP2456786A1 (en) 2012-05-30
CA2768938C (en) 2019-05-14
ES2702274T3 (es) 2019-02-28
HUE043032T2 (hu) 2019-07-29
JP6701280B2 (ja) 2020-05-27
SG177744A1 (en) 2012-02-28
CY1121159T1 (el) 2020-05-29
JP6170952B2 (ja) 2017-07-26
EP2770061B1 (en) 2018-10-24
WO2011011584A1 (en) 2011-01-27
DK2770061T3 (en) 2019-01-07
AU2010276194B2 (en) 2012-02-02
CN102482329A (zh) 2012-05-30
KR20120068838A (ko) 2012-06-27
ME01720B (me) 2014-09-20
PT2456786E (pt) 2014-03-25
AU2010276194A1 (en) 2011-11-24
EP2456786B1 (en) 2014-01-08
TR201819229T4 (tr) 2019-01-21
HRP20181996T1 (hr) 2019-03-22
PL2456786T5 (pl) 2017-10-31
PL2770061T3 (pl) 2019-02-28
SI2456786T2 (sl) 2017-08-31
EA201270191A1 (ru) 2012-12-28
US20160076055A1 (en) 2016-03-17
ES2455544T3 (es) 2014-04-16
HK1201557A1 (en) 2015-09-04
RS58042B1 (sr) 2019-02-28
EP2770061A1 (en) 2014-08-27
EP2456786B2 (en) 2017-04-19
NZ597804A (en) 2013-10-25
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
HRP20140327T1 (hr) 2014-05-09
PL2456786T3 (pl) 2014-06-30
EA032403B1 (ru) 2019-05-31
HRP20140327T4 (hr) 2017-11-03
JP2018198616A (ja) 2018-12-20
DK2456786T4 (en) 2017-08-07
JP2013500015A (ja) 2013-01-07
DK2456786T3 (en) 2014-03-24
CA2768938A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
HRP20140327T1 (hr) Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
ES3041285T3 (en) A vaccine for use in the prophylaxis and/or treatment of a disease
Kaufmann et al. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond
JP2015512263A5 (sr)
JP2004508808A5 (sr)
JP2013500015A5 (sr)
JP2017079787A (ja) 発現系
ES2427139T3 (es) Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
Grasso et al. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein
WO2010040023A2 (en) Methods and compositions for protein delivery
RU2015155821A (ru) Вакцины против малярии
JP2015096070A5 (sr)
CN1362885A (zh) 使用仙台病毒载体的aids病毒疫苗
MD3390430T2 (ro) Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora
JP2020502262A5 (sr)
JP2012520084A5 (sr)
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
Uhlig et al. Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response
US20220380412A1 (en) Compositions comprising v2 opt hiv envelopes
JP2014530000A5 (sr)
AU2019363172A1 (en) Fusion protein
WO2001070262A3 (en) A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins
RU2020125098A (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
US20230302083A1 (en) Highly-networked coronavirus immunogen composition